Syntara Limited (SNT.AX) Deep Dive Video

Summary

A restructured ASX micro-cap biotech betting on first-in-class pan-LOX inhibition—five 2026 readouts could unlock a major re-rating, but the path is highly binary and partner-dependent.

View SNT.AX stock page · Read the SNT.AX research report

Loading the video player…